Back to Results
First PageMeta Content
Generally Accepted Accounting Principles / Taxation / Financial statements / Balance sheet / Income tax in the United States / Deferral / Net income / Income tax / Royalties / Accountancy / Finance / Business


April 29, 2013 Astex Pharmaceuticals Reports 2013 First Quarter Financial Results Data reported at AACR on several preclinical and clinical programs Ends quarter with $137 million in cash & marketable securities First q
Add to Reading List

Open Document

File Size: 24,76 KB

Share Result on Facebook

City

DUBLIN / /

Company

MGI PHARMA / Novartis / Astex Pharmaceuticals Inc. / Eisai Corporation of North America / First data / Conference Call Information Astex Pharmaceuticals / Astex Therapeutics Limited / Astex Pharmaceuticals Astex Pharmaceuticals / AstraZeneca / /

Country

United Kingdom / /

Currency

USD / /

Event

Earnings Announcement / M&A / FDA Phase / Conference Call / /

Facility

Institute of Cancer Research / /

IndustryTerm

treatment of platinum-resistant ovarian cancer / pharmaceutical / biotechnology analysts / /

MedicalCondition

different tumor / myelodysplastic syndromes / platinum-resistant ovarian cancer / hepatocellular cancer / acute myeloid leukemia / /

Organization

American Association of Cancer Research / Institute of Cancer Research / /

Person

James S.J. Manuso / /

Position

General / chief executive officer and chairman / /

Product

Dacogen / SGI-110 / PI3K/AKT / AT13387 / /

ProvinceOrState

California / /

PublishedMedium

Cancer Research / /

Technology

biotechnology / /

URL

http /

SocialTag